DX-88 and HAE: a developmental perspective.

Transfus Apher Sci

Dyax Inc, 300 Technology Square, Cambridge, MA 02139, USA.

Published: December 2003

An example of an approach to the developmental philosophy of novel recombinant products is explored by using the exemplar of Hereditary Angioedema (HAE). Plasma kallikrein is believed to be an important mediator of angioedema in patients with genetic deficiency of C1 esterase inhibitor (HAE patients). DX-88, a novel Kunitz domain produced by phage display (a powerful method of generating novel binders to potentially therapeutic targets), is a potent and selective inhibitor of plasma kallikrein which in early clinical studies demonstrates a useful efficacy/safety ratio in the treatment of acute attacks of HAE.

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1473-0502(03)00170-8DOI Listing

Publication Analysis

Top Keywords

plasma kallikrein
8
dx-88 hae
4
hae developmental
4
developmental perspective
4
perspective example
4
example approach
4
approach developmental
4
developmental philosophy
4
philosophy novel
4
novel recombinant
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!